The magnesium included as a pharmaceutical excipient in phosphate binders might affect the serum magnesium levels of dialysis patients
Nobuo Nagano(Kirin (Japan)), Tetsuya Ogawa(Nihon University), Masayo Honda(Hidaka Hospital), Kosaku Nitta(Tokyo Women's Medical University), Kyoko Ito, Tetsuo Ando, Ayaka Tagahara(Hidaka Hospital), Satoru Sunaga(Hidaka Hospital), Noriko Tamei(Hidaka Hospital), Atsushi Nohara(Kanazawa University), Hiroshi Sakura(Tokyo Women's Medical University Adachi Medical Center), Takaaki Tsutsui(Hidaka Hospital), Ayako Hoshi(Hidaka Hospital), Tomoi Nohara(Hidaka Hospital)
Cited by 5
Related Papers
An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013)
|Therapeutic Apheresis and Dialysis|2015|425
Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017
|Journal of Atherosclerosis and Thrombosis|2018|226
Guidelines for the Management of Familial Hypercholesterolemia
|Journal of Atherosclerosis and Thrombosis|2012|177
Annual dialysis data report for 2018, JSDT Renal Data Registry: survey methods, facility data, incidence, prevalence, and mortality
|Renal Replacement Therapy|2020|170